The Bio Report

The World Health Organization estimates that 270 million people worldwide suffer from chronic hepatitis B virus infections, making it a global epidemic that affects more than twice the number of people with hepatitis C and HIV combined. HBV is a leading cause of chronic liver disease and the need for liver transplantation, with up to 1 million people worldwide dying from HBV-related causes each year. While current treatments reduce the viral load, they don’t eliminate it. Assembly Bio is developing a pipeline of therapies aimed at curing HBV. We spoke to John McHutchison, president and CEO of Assembly Bio, about HBV, the company’s efforts to develop a new class of drugs to treat the condition, and what he’s learned from his work at Gilead successfully developing and commercializing therapies for HCV. A note to listeners: As we were publishing this episode Assembly Bio announced plans to discontinue development of its phase 2 candidate ABI-H2158 because safety concerns. The company said it will focus on advanc